Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Redhill Biophrma ADR (RDHL)

Redhill Biophrma ADR (RDHL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 362,119
  • Shares Outstanding, K 37,409
  • Annual Sales, $ 6,290 K
  • Annual Income, $ -42,300 K
  • 60-Month Beta 1.61
  • Price/Sales 56.97
  • Price/Cash Flow N/A
  • Price/Book 9.77
Trade RDHL with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.22
  • Number of Estimates 1
  • High Estimate -0.22
  • Low Estimate -0.22
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +26.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.14 +7.33%
on 10/22/20
10.84 -9.50%
on 10/19/20
-0.28 (-2.78%)
since 09/25/20
3-Month
6.60 +48.64%
on 07/29/20
11.35 -13.57%
on 09/16/20
+2.99 (+43.84%)
since 07/24/20
52-Week
3.26 +200.73%
on 03/18/20
11.35 -13.57%
on 09/16/20
+3.51 (+55.71%)
since 10/25/19

Most Recent Stories

More News
RedHill Biopharma Presents New Data from Talicia(R)'s Phase 3 Studies at ACG 2020 Focused on Achieving Successful First-Line Treatment in H. pylori Eradication

H. pylori eradication rates with clarithromycin-based triple therapy were found to be predictably low in the Phase 3 trial, with antibiotic resistance a contributing factor. Despite declining efficacy,...

RDHL : 9.81 (+1.34%)
RedHill's (RDHL) RHB-204 Gets FDA Orphan Drug Designation

RedHill (RDHL) gets Orphan Drug status from the FDA for the treatment of nontuberculous mycobacteria (NTM) disease.

ACRX : 1.7100 (-2.84%)
RDHL : 9.81 (+1.34%)
EARS : 0.8599 (-1.41%)
AMRX : 4.84 (-7.10%)
RedHill Biopharma Announces FDA Orphan Drug Designation for RHB-204 for the Treatment of NTM Infections

RHB-204 Phase 3 study in pulmonary NTM infections is planned to be initiated in the coming weeks

RDHL : 9.81 (+1.34%)
RedHill Biopharma gibt Partnerschaften zur Erweiterung der Produktion fur COVID-19-Medikamentenkandidat Opaganib bekannt

Zusammenarbeit mit europaischen und kanadischen Herstellern zur Erweiterung der Opaganib-Herstellung in grossem Massstab starkt Fertigungskapazitaten in Vorbereitung auf potentielle Antrage fur Notfallgenehmigungen...

RDHL : 9.81 (+1.34%)
RedHill Biopharma annuncia le partnership per ampliare la produzione di opaganib, candidato terapeutico per il trattamento del COVID-19

Le collaborazioni con fornitori europei e canadesi per l'accelerazione su vasta scala della produzione di opaganib rafforzano ulteriormente la capacita e le potenzialita produttive, in previsione delle...

RDHL : 9.81 (+1.34%)
RedHill Biopharma Announces Partnerships to Expand Manufacturing for COVID-19 Therapeutic Candidate Opaganib

Collaborations with European and Canadian suppliers for large-scale ramp-up of opaganib manufacturing further strengthens manufacturing capabilities and capacity, in preparation for potential emergency...

RDHL : 9.81 (+1.34%)
Klinische COVID-19-Studie zu Opaganib von RedHill Biopharma besteht zweite Uberprufung durch unabhangigen Ausschuss

Safety Monitoring Committee (SMC) empfiehlt nach zweiter planmassiger unabhangiger Uberprufung einstimmig die unveranderte Fortsetzung der US-Phase-II-Studie zur Behandlung von COVID-19 mit Opaganib

RDHL : 9.81 (+1.34%)
Lo studio su Opaganib nel trattamento del COVID-19 di RedHill Biopharma passa la seconda valutazione del Comitato indipendente

La seconda valutazione pre-programmata del Comitato indipendente di monitoraggio della sicurezza (SMC) raccomanda all'unanimita la continuazione senza variazioni dello studio di fase 2 con opaganib per...

RDHL : 9.81 (+1.34%)
RedHill Biopharma Adds Israel Rights to Movantik(R) From AstraZeneca

RedHill obtains Israel rights to Movantik from AstraZeneca, giving RedHill global rights, excluding Europe and Canada

RDHL : 9.81 (+1.34%)
RedHill Biopharma's Opaganib COVID-19 Study Passes Second Independent Committee Review

Second pre-scheduled independent Safety Monitoring Committee (SMC) review unanimously recommends continuation without change of the U.S. Phase 2 study with opaganib in COVID-19

RDHL : 9.81 (+1.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

RedHill Biopharma Ltd. is a specialty biopharmaceutical company, primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases. RedHill promotes the gastrointestinal drug Aemcolo(TM) in the U.S. and is planning to launch Talicia(TM) in...

See More

Key Turning Points

2nd Resistance Point 10.08
1st Resistance Point 9.95
Last Price 9.81
1st Support Level 9.61
2nd Support Level 9.40

See More

52-Week High 11.35
Last Price 9.81
Fibonacci 61.8% 8.26
Fibonacci 50% 7.31
Fibonacci 38.2% 6.35
52-Week Low 3.26

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar